CA index name: L-Methioninamide, N-[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]glycyl-4-aminobenzoyl-L-glutaminyl-L-tryptophyl -L-alanyl-L-valylglycyl-L-histidyl-L-leucyl-
Sequence: DOTA-Gly-4-Abz-Gln-Trp-Ala-Val-Gly-His-Leu-Met-NH₂; DOTA = N-[[4,7,10-tris(carboxymethyl)-1,4,7,10-tetraazacyclododec-1-yl]acetyl]-; 4-Abz = 4-aminobenzoyl; Supplied as acetate salt
Molar mass 1502.70
CAS RN [721937-56-0] (net peptide)
Purity ≥ 97 %
- Colorless to off-white freeze-dried solid
CoA: appearance, MS (identity), HPLC (purity)
Chen J. et al. Synthesis, stabilization and formulation of [¹⁷⁷Lu]Lu-AMBA, a systemic radiotherapeutic agent for Gastrin Releasing Peptide receptor positive tumors. Appl Radiat Isot. 2008, 66, 497–505.
Waser B. et al. Selective in vitro targeting of GRP and NMB receptors in human tumours with the new bombesin tracer 177Lu-AMBA. Eur. J. Nucl. Med. Mol. Imaging. 2007, 34, 95–100.
Lantry L.E. et al. ¹⁷⁷Lu-AMBA: Synthesis and characterization of a selective ¹⁷⁷Lu-labeled GRP-R agonist for systemic radiotherapy of prostate cancer. J. Nucl. Med. 2006, 47, 1144–52.
Nunn A.D. et al. Preclinical evaluation of ¹⁷⁷Lu-AMBA, a radiolabelled peptide for systemic radiotherapy and imaging of prostate cancer by targeting gastrin releasing peptide receptors. Eur. J. Cancer Suppl. 2004, 2, 89.
Add to inquiry
|Product||Product No.||Filling amount||Quantity|
|/products/chemicals/chemical/483e0f4f-94b7-4c4b-acfa-0bef4ad4dafb||Chemicals||Product No.: 9714||Filling amount: 1 mg|
|/products/chemicals/chemical/483e0f4f-94b7-4c4b-acfa-0bef4ad4dafb||Chemicals||Product No.: 9714||Filling amount: 10 mg|
|/products/chemicals/chemical/483e0f4f-94b7-4c4b-acfa-0bef4ad4dafb||Chemicals||Product No.: 9714|